After a period of time, tumor cells were able to restore drug sensitivity again, suggesting that clonal evolution persisted, and ctDNA can be used to dynamically monitor KRAS mutation levels, providing a basis for reapplication of anti-EGFR drugs [102]. Here, EGFR is linked to neoplasm.